Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Placebo/Adolescents

Placebo for Adolescents

3 papers and 13 clinical trials exploring placebo as a treatment for adolescents.

CompoundComparator / Control

Placebo

Placebo is the most widely referenced comparator in psychedelic clinical research, appearing in over 500 trials. Understanding how placebos are designed, administered, and interpreted is essential to evaluating the evidence base for psychedelic-assisted therapies — and one of the field’s most contested methodological challenges.

Full Placebo profile
IndicationApproximately 300 million adolescents worldwide.

Adolescents

Psychedelic use among adolescents presents a complex interplay between cultural context, potential therapeutic benefits, and risks associated with mental health. Recent research suggests that while Western perspectives are largely negative, there is a growing interest in the potential for psychedelics to support mental health treatment in this demographic, particularly in therapeutic settings.

Full Adolescents profile

Academic Research

3 papers
Open Accessindividual

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

This secondary analysis of an RCT (n=59) investigates the impact of psilocybin-assisted therapy (PAT) and escitalopram (SSRI) on responsiveness to emotional stimuli in patients with moderate-to-severe major depressive disorder over a 6-week trial period. Responses to emotional faces were reduced in the SSRI group, not the psilocybin group at the follow-up.

Published
May 7, 2025
Journal
American Journal of Psychiatry
Authors
Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L.
Paywallmeta

MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial

This study (2022) analysed data from two Phase II and one Phase III trials from MAPS where MDMA-assisted therapy (MDMA-AT) was used to treat PTSD in order to compare the efficacy and safety of MDMA-AT between Black, Indigenous, and People of Color (BIPOC) and non-Hispanic White participants. No significant ethnoracial difference in CAPS-5 scores was observed while BIPOC participants trended toward greater reductions following MDMA-AT.

Published
June 21, 2022
Journal
Journal of Psychopharmacology
Authors
Ching, T. H., Williams, M. T., Wang, J. B., Jerome, L., Yazar-Klosinski, B., Emerson, A., Doblin, R.
Open Accessmeta

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

This pooled analysis (n=139) of double-blind, placebo-controlled studies reviews the role of genetic polymorphisms in CYP2C19, CYP2B6, and CYP1A2 in the metabolism of MDMA in humans. The research shows affirmed that these enzymes play a significant role in the metabolism of MDMA to MDA in humans and that genetic polymorphism in CYP2C19 could moderate MDMA's cardiovascular toxicity.

Published
March 1, 2017
Journal
European Neuropsychopharmacology
Authors
Vizeli, P., Schmid, Y., Prestin, K., Meyer Zu Schwabedissen, H. E., Liechti, M. E.

Clinical Trials

13 trials
Not yet recruitingPhase III

Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents

This randomised, double-blind, placebo-controlled Phase III trial (n=60) will investigate the efficacy and safety of subcutaneous ketamine (35-70mg/70kg, twice weekly for four weeks) as an add-on treatment for adolescents experiencing a major depressive episode with suicidal ideation and/or behaviour.

Started
May 1, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06957704
RecruitingPhase I

PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm

This triple-blind, placebo-controlled trial (n=30) will investigate the effects of a sub-hallucinogenic dose of psilocybin (5 mg) combined with Imagery Re-Scripting (ImRS) on cognitive processes and self-harm behaviour in young people aged 16–25.

Started
March 1, 2025
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT06798636
RecruitingPhase NA

Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation (KSI)

This double-blinded, randomized, placebo-controlled, parallel-arm pilot trial (n=20) will investigate the efficacy of intravenous ketamine (0.5 mg/kg IV) versus saline for emergency department treatment of suicidal ideation in adolescents.

Started
January 15, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06366334
Unknown statusPhase III

Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation

This double-blinded, randomized, placebo-controlled, parallel-arm pilot trial (n=20) will investigate the efficacy of intravenous ketamine for emergency department treatment of suicidal ideation (SI) in adolescents.

Started
June 1, 2023
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05468840
RecruitingPhase III

Ketamine Treatment of Youth Suicide Attempters

This double-blind, placebo-controlled trial (n=140) investigates the efficacy and safety of ketamine in rapidly reducing severe suicide risk among youth aged 14-30 who have attempted suicide.

Started
June 27, 2022
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT04763343
TerminatedPhase I/II

Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics (Keta4SI)

This Phase I/II interventional trial (n=96) will investigate the use of intravenous ketamine for the rapid reduction of suicidality in paediatric patients presenting with suicidal ideation (SI) in the emergency department (ED).

Started
June 1, 2022
Type
interventional
Blinding
triple
Randomized
Yes
Registry ID
NCT04955470

Explore further

Search all Placebo papers Search all Adolescents trials Full Placebo profile Full Adolescents profile